WO2022151851A8 - Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée - Google Patents

Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée Download PDF

Info

Publication number
WO2022151851A8
WO2022151851A8 PCT/CN2021/133817 CN2021133817W WO2022151851A8 WO 2022151851 A8 WO2022151851 A8 WO 2022151851A8 CN 2021133817 W CN2021133817 W CN 2021133817W WO 2022151851 A8 WO2022151851 A8 WO 2022151851A8
Authority
WO
WIPO (PCT)
Prior art keywords
immune cell
antigen receptor
chimeric antigen
engineered immune
blocking molecule
Prior art date
Application number
PCT/CN2021/133817
Other languages
English (en)
Chinese (zh)
Other versions
WO2022151851A1 (fr
Inventor
张鸿声
Original Assignee
上海雅科生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海雅科生物科技有限公司 filed Critical 上海雅科生物科技有限公司
Priority to EP21919042.8A priority Critical patent/EP4279585A1/fr
Priority to JP2023542493A priority patent/JP2024502632A/ja
Priority to CA3204370A priority patent/CA3204370A1/fr
Priority to AU2021418636A priority patent/AU2021418636A1/en
Priority to KR1020237027583A priority patent/KR20230134133A/ko
Publication of WO2022151851A1 publication Critical patent/WO2022151851A1/fr
Priority to US18/351,466 priority patent/US20240075143A1/en
Publication of WO2022151851A8 publication Critical patent/WO2022151851A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4633—Antibodies or T cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une cellule immunitaire génétiquement modifiée ciblant CD7, un récepteur antigénique chimérique (ou CAR pour « chimeric antigen receptor »), une molécule de blocage de CD7 et une utilisation associée. Un ligand naturel du CD7 humain est utilisé pour remplacer une séquence d'anticorps pour servir de domaine de reconnaissance d'antigène d'une cellule CAR-T ou CAR-NK spécifique de CD7. Des réactions cellulaires et humorales produites par un hôte peuvent être évitées grâce à l'utilisation de CD7 humain en tant que domaine de reconnaissance d'antigène dans le CAR spécifique de CD7, ce qui permet d'obtenir une durabilité à long terme et une meilleure efficacité de la cellule CAR-T.
PCT/CN2021/133817 2021-01-12 2021-11-29 Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée WO2022151851A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP21919042.8A EP4279585A1 (fr) 2021-01-12 2021-11-29 Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée
JP2023542493A JP2024502632A (ja) 2021-01-12 2021-11-29 Ｃｄ７を標的とする改変免疫細胞、キメラ抗原受容体、ｃｄ７ブロッキング分子およびその応用
CA3204370A CA3204370A1 (fr) 2021-01-12 2021-11-29 Cellule immunitaire genetiquement modifiee ciblant cd7, recepteur antigenique chimerique, molecule de blocage de cd7 et utilisation associee
AU2021418636A AU2021418636A1 (en) 2021-01-12 2021-11-29 Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof
KR1020237027583A KR20230134133A (ko) 2021-01-12 2021-11-29 Cd7을 표적화하는 조작된 면역 세포, 키메라 항원 수용체,cd7 차단 분자 및 용도
US18/351,466 US20240075143A1 (en) 2021-01-12 2023-07-12 Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110036169.2 2021-01-12
CN202110036169.2A CN113234682B (zh) 2021-01-12 2021-01-12 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/351,466 Continuation US20240075143A1 (en) 2021-01-12 2023-07-12 Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof

Publications (2)

Publication Number Publication Date
WO2022151851A1 WO2022151851A1 (fr) 2022-07-21
WO2022151851A8 true WO2022151851A8 (fr) 2023-10-19

Family

ID=77130068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/133817 WO2022151851A1 (fr) 2021-01-12 2021-11-29 Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée

Country Status (8)

Country Link
US (1) US20240075143A1 (fr)
EP (1) EP4279585A1 (fr)
JP (1) JP2024502632A (fr)
KR (1) KR20230134133A (fr)
CN (3) CN115786271A (fr)
AU (1) AU2021418636A1 (fr)
CA (1) CA3204370A1 (fr)
WO (1) WO2022151851A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786271A (zh) * 2021-01-12 2023-03-14 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
CN114716564B (zh) * 2021-12-20 2023-02-28 四川大学华西医院 基于sectm1构建的嵌合抗原受体免疫细胞制备及其应用
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
CN114560943B (zh) * 2022-02-28 2022-12-16 先进生物(苏州)有限公司 Cd7-car-t细胞及其制备方法和应用
CN114685662B (zh) * 2022-03-30 2022-12-27 河北森朗生物科技有限公司 抗cd7纳米抗体、衍生物及其在肿瘤治疗中的应用
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
CN116003631B (zh) * 2022-11-15 2024-01-26 江苏元晟生物科技有限公司 靶向cd7的人源化抗体及其应用
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091616A1 (fr) * 2015-02-27 2022-11-23 iCell Gene Therapeutics LLC Récepteurs d'antigènes chimériques (car) ciblant des malignités hématologiques; leurs compositions et leurs procédés d'utilisation
WO2017213979A1 (fr) * 2016-06-06 2017-12-14 St. Jude Children's Research Hospital Récepteur d'antigène chimérique anti-cd7 et son procédé d'utilisation
KR20240099512A (ko) * 2016-11-22 2024-06-28 싱가포르국립대학교 T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
WO2018231871A1 (fr) * 2017-06-12 2018-12-20 Emory University Récepteur d'antigène chimérique (car) ciblant l'antigène de lymphocyte t et utilisations dans des thérapies cellulaires
KR20210091250A (ko) * 2018-11-14 2021-07-21 메디식스 테라퓨틱스 피티이 엘티디. Car-t 세포를 생성하기 위한 이중유전자 벡터 및 이의 용도
CN110760007B (zh) * 2019-11-21 2022-08-26 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
CN115786271A (zh) * 2021-01-12 2023-03-14 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用

Also Published As

Publication number Publication date
EP4279585A1 (fr) 2023-11-22
CA3204370A1 (fr) 2022-07-21
US20240075143A1 (en) 2024-03-07
CN115786271A (zh) 2023-03-14
JP2024502632A (ja) 2024-01-22
CN113234682A (zh) 2021-08-10
CN113234682B (zh) 2023-02-21
AU2021418636A1 (en) 2023-08-24
KR20230134133A (ko) 2023-09-20
CN115947852A (zh) 2023-04-11
WO2022151851A1 (fr) 2022-07-21

Similar Documents

Publication Publication Date Title
WO2022151851A8 (fr) Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée
AU2019255744A8 (en) IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof
NZ616254A (en) Complexes of il-15 and il-15ralpha and uses thereof
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2007146172A8 (fr) Anticorps reconnaissant un épitope contenant un hydrate de carbone du cd-43 et de l'ace exprimé sur des cellules cancéreuses, et procédés les utilisant
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
MX354143B (es) Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
FI1897548T4 (fi) T-solujen säätely
WO2009014708A3 (fr) Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
NO20062674L (no) Optimalisert uttrykking av HPV58-L1 i gjaer
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
EA201071068A1 (ru) Антитела к tyrp1
CR20220611A (es) Anticuerpos anti-tigit
ZA202008095B (en) Humanized antibodies against psma
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2022016300A (es) Anticuerpo anti-trop2.
WO2022067269A3 (fr) Anticorps contre le sars-cov-2
MX2023013726A (es) Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso.
WO2022066965A3 (fr) Immunothérapie ciblant des antigènes sox2
CL2023003005A1 (es) Polipéptido de unión a gucy2c y usos del mismo.
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2023196947A3 (fr) Procédés d'activation et d'expansion de cellules tueuses naturelles modifiées et combinaisons avec des anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21919042

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3204370

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023542493

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20237027583

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020237027583

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021418636

Country of ref document: AU

Date of ref document: 20211129

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11202305254P

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2021919042

Country of ref document: EP

Effective date: 20230814